Serum levels of soluble CD25 as a marker for hepatocellular carcinoma

Cabrera,Roniel; Fitian,Asem  I.; Ararat,Miguel; Xu,Yiling; Brusko,Todd; Wasserfall,Clive; Atkinson,Mark   A.; Liu,Chen; Nelson,David   R.

doi:10.3892/ol.2012.826

October 2012 Volume 4 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October 2012 Volume 4 Issue 4

Full Size Image

Article

Serum levels of soluble CD25 as a marker for hepatocellular carcinoma

Authors:
- Roniel Cabrera
- Asem I. Fitian
- Miguel Ararat
- Yiling Xu
- Todd Brusko
- Clive Wasserfall
- Mark A. Atkinson
- Chen Liu
- David R. Nelson
View Affiliations / Copyright

Affiliations: Section of Hepatobiliary Diseases, Department of Medicine, University of Florida, Gainesville, FL 32610-0214, USA, Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610-0214, USA, Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL 32610-0214, USA
Pages: 840-846
|
Published online on: July 26, 2012

https://doi.org/10.3892/ol.2012.826
Expand metrics +

Abstract

In a previous study, we showed that the level of soluble CD25 (sCD25) was elevated in a small series of patients with hepatocellular carcinoma (HCC). In the present study, we determined the capacity of serum levels of sCD25 to detect the presence and the early stage of HCC using a larger cohort of HCC patients and evaluated the correlation between sCD25 level and tumor burden. Serum levels of sCD25 were quantified using ELISA in patients with HCC (n=145), controls with advanced fibrosis (n=61) and healthy control subjects (n=30). The levels of sCD25 in patients with HCC (median, 6,955 pg/ml) were significantly higher than those in cirrhosis‑only patients (4,310 pg/ml; P<0.0001). At a cut-off value of 2,180 pg/ml, sCD25 had a sensitivity of 92.3% and a specificity of 37.7% in detecting HCC presence [area under the curve (AUC) of 0.685; P<0.0001]. By comparison, α-fetoprotein (AFP) had a sensitivity of 53.8% and a specificity of 86.8% at a cut-off value of 32.8 ng/ml (AUC=0.755; P<0.0001) for HCC presence detection. For early HCC, the sensitivity of sCD25 was 89.6% and its specificity was 39.3% (AUC=0.630; P<0.0001) at a cut-off value of 2,859 pg/ml, while AFP had a sensitivity of 41.7% and a specificity of 82.6% at a cut-off value of 20.6 ng/ml (AUC=0.630; P=0.0257). We also found a significant positive correlation between serum levels of sCD25 and tumor stage. In the present study study, sCD25 was more effective than AFP at detecting the presence and early stages of HCC. This immune factor may hold promise as a novel predictive marker of HCC presence and may be useful in distinguishing early HCC from advanced cirrhosis, currently areas of global unmet need.

View Figures

View References

1.	HB El-SeragHepatocellular carcinomaN Engl J Med36511181127201110.1056/NEJMra100168321992124
2.	SH CaldwellDM CrespoHS KangAM Al-OsaimiObesity and hepatocellular carcinomaGastroenterology127Suppl 1S97S103200410.1053/j.gastro.2004.09.02115508109
3.	G FattovichT StroffoliniI ZagniF DonatoHepatocellular carcinoma in cirrhosis: incidence and risk factorsGastroenterology127Suppl 1S35S50200410.1053/j.gastro.2004.09.01415508101
4.	LL WongWM LimmR SeverinoLM WongImproved survival with screening for hepatocellular carcinomaLiver Transpl6320325200010.1053/lv.2000.487510827233
5.	HB El-SeragJR KramerGJ ChenZ DuanPA RichardsonJA DavilaEffectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USAGut60992997201110.1136/gut.2010.23050821257990
6.	S BenowitzLiver cancer biomarkers struggling to succeedJ Natl Cancer Inst99590591200710.1093/jnci/djk17417440159
7.	M ShermanCurrent status of α-fetoprotein testingGastroenterol Hepatol (NY)71131142011
8.	J BruixM ShermanPractice Guidelines Committee, American Association for the Study of Liver DiseasesManagement of hepatocellular carcinomaHepatology4212081236200510.1002/hep.20933
9.	Y NakamotoLG GuidottiCV KuhlenP FowlerFV ChisariImmune pathogenesis of hepatocellular carcinomaJ Exp Med188341350199810.1084/jem.188.2.3419670046
10.	NA CacalanoJA JohnstonInterleukin-2 signaling and inherited immunodeficiencyAm J Hum Genet65287293199910.1086/30251810417270
11.	R CabreraM AraratM CaoHepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25)Dig Dis Sci55484495201010.1007/s10620-009-0955-519714465
12.	B HoechstLA OrmandyM BallmaierA new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cellsGastroenterology135234243200818485901
13.	B ArunBD CurtiDL LongoElevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemiaCancer J Sci Am62124200010696734
14.	T ManshouriKA DoX WangCirculating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significanceBlood10125072513200310.1182/blood-2002-06-163912446458
15.	RG KnodellKG IshakWC BlackFormulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitisHepatology1431435198110.1002/hep.1840010511
16.	JM LlovetC BrúJ BruixPrognosis of hepatocellular carcinoma: the BCLC staging classificationSemin Liver Dis19329338199910.1055/s-2007-100712210518312
17.	F TrevisaniPE D’IntinoAM Morselli-LabateSerum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV statusJ Hepatol34570575200110.1016/S0168-8278(00)00053-211394657
18.	T SassaT KumadaS NakanoT UematsuClinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinomaEur J Gastroenterol Hepatol1113871392199910.1097/00042737-199912000-00008
19.	Y ShimauchiM TanakaR KuromatsuA simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha- fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patientsOncol Rep72492562000
20.	JA MarreroGL SuW WeiDes-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patientsHepatology3711141121200310.1053/jhep.2003.50195
21.	JA MarreroZ FengY WangAlpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinomaGastroenterology137110118200910.1053/j.gastro.2009.04.00519362088
22.	BI CarrF KankeM WiseS SatomuraClinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United StatesDig Dis Sci52776782200710.1007/s10620-006-9541-2
23.	AS LokRK SterlingJE EverhartHALT-C Trial GroupDes-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinomaGastroenterology138493502201010.1053/j.gastro.2009.10.03119852963
24.	S NakamuraK NousoK SakaguchiSensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor sizeAm J Gastroenterol10120382043200610.1111/j.1572-0241.2006.00681.x16848811
25.	RK SterlingEC WrightTR MorganFrequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis CAm J Gastroenterol1076474201210.1038/ajg.2011.31221931376
26.	AM Di BisceglieRK SterlingRT ChungHALT-C Trial GroupSerum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C trialJ Hepatol43434441200516136646
27.	SK YoonNK LimS HaThe human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinomaCancer Res6454345441200410.1158/0008-5472.CAN-03-366515289352
28.	ME el-HouseiniMS MohammedWM ElshemeyTD HusseinOS DesoukyAA ElsayedEnhanced detection of hepatocellular carcinomaCancer Control12248253200516258497
29.	MF YuenCL LaiScreening for hepatocellular carcinoma: survival benefit and cost-effectivenessAnn Oncol1414631467200310.1093/annonc/mdg40014504044
30.	JA DavilaL HendersonJR KramerUtilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United StatesAnn Intern Med1548593201110.7326/0003-4819-154-2-201101180-0000621242365
31.	B DanieleA BencivengaAS MegnaV TinessaAlpha- fetoprotein and ultrasonography screening for hepatocellular carcinomaGastroenterology127Suppl 1S108S112200410.1053/j.gastro.2004.09.02315508073
32.	MS PepeR EtzioniZ FengPhases of biomarker development for early detection of cancerJ Natl Cancer Inst9310541061200110.1093/jnci/93.14.105411459866

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Serum levels of soluble CD25 as a marker for hepatocellular carcinoma

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles